{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:08:06Z","timestamp":1791896886582,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40256-024-00694-w","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:22:32Z","timestamp":1730092952000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sotatercept: The First FDA-Approved Activin A Receptor IIA Inhibitor Used in the Management of Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"25","author":[{"given":"Josiah","family":"Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-1543","authenticated-orcid":false,"given":"Genevieve","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"694_CR1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"key":"694_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1183\/09059180.00008411","volume":"21","author":"MR Wilkins","year":"2012","unstructured":"Wilkins MR. Pulmonary hypertension: the science behind the disease spectrum. Eur Respir Rev. 2012;21:19\u201326. https:\/\/doi.org\/10.1183\/09059180.00008411.","journal-title":"Eur Respir Rev"},{"key":"694_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.029024","volume":"12","author":"BA Maron","year":"2023","unstructured":"Maron BA. Revised definition of pulmonary hypertension and approach to management: a clinical primer. J Am Heart Assoc. 2023;12: e029024. https:\/\/doi.org\/10.1161\/jaha.122.029024.","journal-title":"J Am Heart Assoc"},{"key":"694_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ahj.2022.12.009","volume":"258","author":"G Benincasa","year":"2023","unstructured":"Benincasa G, Napoli C, Loscalzo J, Maron BA. Pursuing functional biomarkers in complex disease: focus on pulmonary arterial hypertension. Am Heart J. 2023;258:96\u2013113. https:\/\/doi.org\/10.1016\/j.ahj.2022.12.009.","journal-title":"Am Heart J"},{"key":"694_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12265-022-10294-1","volume":"16","author":"G Benincasa","year":"2023","unstructured":"Benincasa G, Maron BA, Affinito O, et al. Association between circulating CD4+ T cell methylation signatures of network-oriented SOCS3 gene and hemodynamics in patients suffering pulmonary arterial hypertension. J Cardiovasc Transl Res. 2023;16:17\u201330. https:\/\/doi.org\/10.1007\/s12265-022-10294-1.","journal-title":"J Cardiovasc Transl Res"},{"key":"694_CR6","unstructured":"PharmaCompass. Sotatercept. Published July 29, 2005. https:\/\/www.pharmacompass.com\/chemistry-chemical-name\/sotatercept. Accessed 25 Apr 2024"},{"key":"694_CR7","unstructured":"Winrevair (Sotatercept) [package insert]. Rahway: Merck Sharp & Dohme LLC; 2024."},{"key":"694_CR8","unstructured":"Sotatercept. In: Lexi-Drugs. Lexi-Comp, Inc. Updated April 1, 2024. Accessed 1 Apr 2024."},{"key":"694_CR9","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/nejmoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384:1204\u201315. https:\/\/doi.org\/10.1056\/nejmoa2024277.","journal-title":"N Engl J Med"},{"key":"694_CR10","doi-asserted-by":"publisher","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 388:1478\u201390. https:\/\/doi.org\/10.1056\/nejmoa2213558.","DOI":"10.1056\/nejmoa2213558"},{"key":"694_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjopen\/oead086","volume":"3","author":"V Jaiswal","year":"2023","unstructured":"Jaiswal V, Peng Ang S, Agrawal V, et al. Sotatercept for the treatment of pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Eur Heart J. 2023;3:1\u20133. https:\/\/doi.org\/10.1093\/ehjopen\/oead086.","journal-title":"Eur Heart J"},{"key":"694_CR12","unstructured":"Merck. Merck presents new analyses supporting the promising potential of sotatercept, its investigational medicine for adults with pulmonary arterial hypertension (PAH). https:\/\/www.merck.com\/news\/merck-presents-new-analyses-supporting-the-promising-potential-of-sotatercept-its-investigational-medicine-for-adults-with-pulmonary-arterial-hypertension-pah\/. Published online September 11, 2023. Accessed 6 May 2024."},{"key":"694_CR13","unstructured":"ClinicalTrials.gov. A long-term follow-up study of sotatercept for PAH treatment (MK-7962-004). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04796337. Updated June 21, 2024. Accessed 6 May 2024."},{"key":"694_CR14","unstructured":"Merck. FDA approves Merck\u2019s WINREVAIRTM (sotatercept-csrk), a first-in-class treatment for adults with pulmonary arterial hypertension (PAH, WHO Group 1). https:\/\/www.merck.com\/news\/fda-approves-mercks-winrevair-sotatercept-csrk-a-first-in-class-treatment-for-adults-with-pulmonary-arterial-hypertension-pah-who-group-1\/. Published March 26, 2024. Accessed 6 May 2024."},{"key":"694_CR15","unstructured":"Prime Therapeutics. High-cost therapy profile. https:\/\/www.primetherapeutics.com\/news\/high-cost-therapy-profile-4\/. Published March 14, 2024. Accessed 20 June 2024."},{"key":"694_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.hlc.2023.10.010","volume":"33","author":"G Benincasa","year":"2024","unstructured":"Benincasa G, Strozziero MG, Trama U, Napoli C. Unsolved issues on beneficial effects of combination therapy with sotatercept in pulmonary arterial hypertension. Heart Lung Circ. 2024;33:12\u20133. https:\/\/doi.org\/10.1016\/j.hlc.2023.10.010.","journal-title":"Heart Lung Circ"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00694-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00694-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00694-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:15:18Z","timestamp":1738062918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00694-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00694-w","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"15 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Josiah Villanueva, Jasmine Wade, Ana Torres, Genevieve Hale, and Huy Pham declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing not applicable to this article as no datasets were generated during the writing of this review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed to study conception and design, material preparation, and data collection and analysis, as well as collaborated and commented on all versions of the manuscript and read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}